...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Promissory Notes

This is ridiculous that a firm can't repay this small  amount by March of '22. Also why would someone secure this amount when the original note was unsecured? Makes no sense...as, worst case, they would have lots of time to renegotiate the unsecured note in March '22.

Share
New Message
Please login to post a reply